Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
2.850
-0.140 (-4.68%)
At close: Apr 1, 2025, 4:00 PM
2.844
-0.006 (-0.22%)
After-hours: Apr 1, 2025, 5:13 PM EDT
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
56
Market Cap
243.75M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AVIR News
- 1 day ago - Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - GlobeNewsWire
- 6 days ago - Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - GlobeNewsWire
- 6 days ago - The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
- 11 days ago - Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewsWire
- 13 days ago - Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 - GlobeNewsWire
- 26 days ago - Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 - GlobeNewsWire